Previous studies showed that adjusting thienopyridine treatment in patients after primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction, according to the CYP2C19 genotype, can improve a patient’s outcome [31, 32]. The gene discussed is CYP2C19; the disease is ST Elevation Myocardial Infarction.